SynthesisThe Cochrane database of systematic reviews2009
Haloperidol plus promethazine for psychosis-induced aggression.
Synthesis in The Cochrane database of systematic reviews, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 6 syntheses or guidelines pooled it, 203 citations in OpenAlex.
- Rapid Tranquilization for Psychiatric Patients with Psychomotor Agitation: What is Known About it?The Psychiatric quarterly · 2017Pooled it
- Droperidol for psychosis-induced aggression or agitation.The Cochrane database of systematic reviews · 2016Pooled it
- Haloperidol for long-term aggression in psychosis.The Cochrane database of systematic reviews · 2016Pooled it
- Haloperidol plus promethazine for psychosis-induced aggression.The Cochrane database of systematic reviews · 2016Pooled it
- Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses.The Cochrane database of systematic reviews · 2012Pooled it
- Chlorpromazine for psychosis induced aggression or agitation.The Cochrane database of systematic reviews · 2010Pooled it
- Functions of medial hypothalamic and mesolimbic dopamine circuitries in aggression.Current opinion in behavioral sciences · 2018Article
- Benzodiazepines for psychosis-induced aggression or agitation.The Cochrane database of systematic reviews · 2017Review
- [Pharmacotherapy of psychiatric acute and emergency situations: General principles].Der Nervenarzt · 2015Review
- A Role for Oxytocin in the Etiology and Treatment of Schizophrenia.Frontiers in endocrinology · 2015Review
- [Psychotropic agents in emergency medicine].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2014Review
- [Psychopharmacotherapy in emergency medicine].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2013Review
- Pharmacological management of acute and persistent aggression in forensic psychiatry settings.CNS drugs · 2011Review
- Using the needs of WHO to prioritise Cochrane reviews: The case of antipsychotic drugs.International journal of mental health systems · 2011Article
- The impact of a standardised intramuscular sedation protocol for acute behavioural disturbance in the emergency department.BMC emergency medicine · 2010Article
- Packages of care for schizophrenia in low- and middle-income countries.PLoS medicine · 2009Article
Corrections and comments
- Commented on by
- Updated by
- Update of
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHealth services often manage agitated or violent people, and for emergency psychiatric services such behaviour is particularly prevalent (10%). The drugs used in this situation should ensure that the person swiftly and safely regains composure.
objectivesTo examine whether haloperidol plus promethazine is an effective treatment for psychosis induced agitation/aggression. SEARCH STRATEGY: We searched the Cochrane Schizophrenia Group's Register (January 2008). SELECTION CRITERIA: We included all randomised clinical trials involving aggressive people with psychosis for which haloperidol plus promethazine was being used. DATA COLLECTION AND ANALYSIS: We reliably selected, quality assessed and extracted data from all relevant studies. For binary outcomes we calculated standard estimations of risk ratio (RR) and their 95% confidence intervals (CI). Where possible we estimated weighted number needed to treat or harm (NNT/H). MAIN
resultsWe identified four relevant high quality studies. One compared the haloperidol plus promethazine mix with midazolam (n=301), one with lorazepam (n=200), one with haloperidol alone (n=316) and one with olanzapine IM (n=300). In Brazil, haloperidol plus promethazine was an effective means of tranquillisation with over two thirds of people being tranquil or sedated by 30 minutes, but midazolam was more swift (n=301, RR 2.9 CI 1.75 to 4.80, NNH 5 CI 3 to 12). In India, compared with lorazepam, more people were tranquil or sedated by 30 minutes if allocated to the combination treatment (n=200, RR 0.26 CI 0.10 to 0.68, NNT 8 CI 6 to 17). Over the next few hours of treatment reported differences are negligible. One person given midazolam had respiratory depression (0.7%, reversed by flumazenil); one given lorazepam (1%) had respiratory difficulty. About 1% of people given any haloperidol treatment experienced a seizure. By 20 minutes intramuscular haloperidol plus promethazine was more tranquillising than intramuscular haloperidol (1 RCT, n=316, RR 0.65 CI 0.49 to 0.87, NNT 7 CI 5 to 17). Haloperidol given without promethazine in this situation causes frequent serious adverse effects (NNH 15 CI 14 to 40). Olanzapine is as rapidly tranquillising as the haloperidol/promethazine combination (1 RCT, n=300, RR tranquil or asleep at 15 mins 0.74 CI 0.38 to 1.41), but did not have an enduring effect and more people needed additional drugs within four hours (1 RCT, n=300, RR 0.48 CI 0.33 to 0.69, NNT 5 CI 4 to 8) and to be re-assessed by the doctor (1 RCT, n=300, RR 0.47 CI 0.30 to 0.73, NNT 6 CI 5 to 12). AUTHORS'
conclusionsAll treatments evaluated within the included studies are effective. Benzodiazepines, however, have the potential to cause respiratory depression, probably midazolam more so than lorazepam, and use of this group of drugs outside of services fully confident of observing for and managing the consequences of respiratory distress is difficult to justify. Haloperidol used on its own is at such risk of generating preventable adverse effects that unless it is the only choice, this evidence directs that this sole treatment should be avoided. Olanzapine IM is valuable when compared with haloperidol plus promethazine but its duration of action is short and re-injection is frequently needed. Haloperidol plus promethazine used in two diverse situations in Brazil and India has much evidence to support its swift and safe clinically valuable effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.